These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9206580)

  • 1. [The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis].
    Piskun RP; Pentiuk AA; Serkova VK; Polesia TL; Savitskaia EA
    Eksp Klin Farmakol; 1997; 60(2):78-85. PubMed ID: 9206580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hyperlipidemias: an update.
    Ranjan N
    Indian J Dermatol Venereol Leprol; 2009; 75(5):452-62. PubMed ID: 19736423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering agents and their meaning in the treatment of the fat metabolism-atherosclerosis functional circle.
    Kuemmerle HP
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):289-96. PubMed ID: 7263106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypolipidemic, hypocholesterolemic and antisclerotic action of the rotenoid glycoside amorphin].
    Kurmukov AG; Aĭzikov MI; Rasulova SA; Makhmudov OKh
    Farmakol Toksikol; 1986; 49(6):54-7. PubMed ID: 3817147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypolipidemic properties of triterpenoids].
    Vasilenko IuK; Lisevitskaia LI; Frolova LM; Parfent'eva EP; Skul'te IV
    Farmakol Toksikol; 1982; 45(5):66-70. PubMed ID: 7140959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of action of antilipemic drugs].
    Bruckert E; Turpin G
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():109-12. PubMed ID: 1285687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.
    Vega GL
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):525-44, vi. PubMed ID: 15262295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
    Jacotot B
    Sem Hop; 1979 Dec 8-15; 55(41-42):1947-55. PubMed ID: 231322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
    Shah PK
    Rev Cardiovasc Med; 2003; 4(3):136-41. PubMed ID: 12949442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel perspective approaches to the therapy of dyslipidaemias].
    Adameová A; Kuzelová M; Svec P
    Ceska Slov Farm; 2005 May; 54(3):103-8. PubMed ID: 15945455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs.
    Idrees GA; Aly OM; Abuo-Rahma Gel-D; Radwan MF
    Eur J Med Chem; 2009 Oct; 44(10):3973-80. PubMed ID: 19450906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The hypolipidemic and antiatherosclerotic action of absorbable and nonabsorbable substances in the intestines].
    Ryzhenkov VE; Chistiakova AM; Okunevich IV
    Patol Fiziol Eksp Ter; 1989; (5):16-9. PubMed ID: 2616207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
    Jacotot B
    Pathol Biol (Paris); 1979 May; 27(5):305-13. PubMed ID: 388303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phosphatidylcholine in the control of arteriosclerosis].
    Salvioli G; Lugli R; Pradelli JM
    Clin Ter; 1984 Oct; 111(1):27-44. PubMed ID: 6238778
    [No Abstract]   [Full Text] [Related]  

  • 15. [The hypolipidemic activity of natural substances].
    Okunevich IV; Kliueva NN; Solov'eva MA; Triufanov VF; Ryzhenkov VE
    Eksp Klin Farmakol; 1992; 55(5):44-7. PubMed ID: 1305452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of hypolipidemic agents].
    Féry F; Balasse EO
    Rev Med Brux; 1997 Feb; 18(1):26-31. PubMed ID: 9132914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dyslipoproteinemias: treatment with lipid regulating drugs].
    Schwandt P
    Fortschr Med; 1990 Feb; 108(6):97-9. PubMed ID: 2323709
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of the effect of hypolipemic drugs in atherosclerosis].
    Beaumont JL
    Nouv Presse Med; 1980 Oct; 9(40):2945-6. PubMed ID: 7443427
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.